Paroxetine versus citalopram treatment of pathological dying after brain injury

Brain Injury

Volumn 13, Issue 10, 1999, Pages 805-811

  Müller, Ulrich ^a   Murai, Toshiya ^a   Bauer Wittmund, Thomas ^b   Von Cramon, D Yves ^a,b  

^a MAX PLANCK INSTITUTE FOR HUMAN COGNITIVE AND BRAIN SCIENCES   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AFFECTIVE NEUROSIS; AGED; ARTICLE; AUTONOMIC NEUROPATHY; BRAIN INJURY; CLINICAL ARTICLE; CLINICAL TRIAL; CRYING; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INTERVIEW; MALE; NAUSEA; NONVERBAL COMMUNICATION; PROVOCATION; RATING SCALE; STATISTICAL ANALYSIS; SYMPTOM; VOMITING;

EID: 14944373663     PISSN: 02699052     EISSN: None     Source Type: Journal    
DOI: 10.1080/026990599121197     Document Type: Article

References (31)

1. ALLMAN, P.: Crying and laughing after brain damage: a confused nomenclature. Journal of Neurology, Neurosurgery and Psychiatry, 52: 1439-1440, 1989.
2. POECK, K.: Pathological laughter and crying. In J. A. M. Frederiks (editor) Clinical Neuropsychology (Handbook of Clinical Neurology 45), (Amsterdam: Elsevier), pp. 219-225, 1985.
3. ZEILIG, G., DRUBACH, D. A., KATZ-ZEILIG, M. et al.: Pathological laughter and crying in patients with closed traumatic brain injury. Brain Injury, 10: 591-597, 1996.
4. ALLMAN, P., HOPE, T. and FAIRBURN, C. G.: Crying following stroke: a report on 30 cases. General Hospital Psychiatry, 14: 315-321, 1992.
5. DARK, F. L., MCGRATH, J. J. and RON, M. A.: Pathological laughing and crying. Australian and New Zealand Journal of Psychiatry, 30: 472-479, 1996.
6. HOUSE, A., DENNIS, M., MOLYNEUX, A. et al.: Emotionalism after stroke. British Medical Journal, 298: 991-994, 1989.
7. MORRIS, P. L. P., ROBINSON, R. G. and RAPHAEL, B.: Emotional lability after stroke. Australian and New Zealand Journal of Psychiatry, 27: 601-605, 1993.
8. ANDERSEN, G., INGEMAN-NIELSEN, M., VESTERGAARD, K. et al.: Pathoanatomical correlation between poststroke pathological crying and damage to brain areas involved in serotonergic neurotransmission. Stroke, 25: 1050-1052, 1994.
9. BROOKSHIRE, R. H.: Control of 'involuntary' crying behavior omitted by a multiple sclerosis patient. Journal of Communication Disorders, 3: 171-176, 1970.
10. ANDERSEN, G., VESTERGAARD, K. and RUS, J. O.: Citalopram for post-stroke pathological crying. Lancet, 342: 837-839, 1993.
11. ROBINSON, R. G., PARIKH, R. M., LIPSEY, J. R. et al.: Pathologic laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry, 150: 286-293, 1993.
12. SCHIFFER, R. B., HERNDON, R. M. and RUDICK, R. A.: Treatment of pathologic laughing and weeping with amitriptyline. New England Journal of Medicine, 312: 1480-1482, 1985.
13. POLLOCK, B. G., MULSANT, B. H., NEBES, R. et al.: Serum anticholmergicity in elderly depressed patients treated with paroxetine or nortriptyline. American Journal of Psychiatry, 155: 1110-1112, 1998.
14. ANDERSEN, G.: Treatment of uncontrolled crying after stroke. Drugs and Aging, 6: 105-111, 1995.
15. JERET, J. S.: Treatment of poststroke pathological crying [letter]. Stroke, 28: 2321, 1997.
16. SILVER, J. M. and YUDOFSKY, S. C.: Pharmacologic treatment of neuropsychiatrie disorders. NeuroRehabilitation, 3: 1-15, 1993.
17. DE JONGHE, F. and SWINKELS, J.: Selective serotonin reuptake inhibitors: relevance of differences in their pharmocological and clinical profiles. CNS Drugs, 7: 452-467, 1997.
18. MÜLLER, U., FRIEBOES, R. and VON CRAMON, D. Y.: Diagnose und therapie emotionaler instabilität nach hirninfarkt. In H. J. Möller, F. Müller-Spahn and G. Kurtz (editors) Aktuelle Perspektiven der Biologischen Psychiatrie (Wien: Springer), pp. 112-116, 1996.
19. ROBINSON, R. G.: The Clinical Neuropsychiatry of Stroke (Cambridge: Cambridge University Press), 1998.
20. HOTOPF, M., LEWIS, G. and NORMAND, C.: Are SSRIs a cost-effective alternative to tricyclics? British Journal of Psychiatry, 168: 404-409, 1996.
21. DAM, M., TONIN, P., DEBONI, A. et al.: Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke, 27: 1211-1214, 1996.
22. NOBLE, S. and BENFIELD, P.: Citalopram: a review of its pharmacology, clinical efficacy and tolerability in the treatment of depression. CNS Drugs, 8: 410-430, 1997.
23. GUNASEKARA, N. S., NOBLE, S. and BENFIELD, P.: Paroxetine: an update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs, 55; 85-120.
24. LAWSON, I. R. and MACLEOD, R. D. M.: The use of imipramine ('tofranil') and other psychotropic drugs in organic emotionalism. British Journal of Psychiatry, 115: 281-285, 1969.
25. CAROSCIO, J. T., COHEN, J. A. and GUDESBLATT, M.: Amitriptyline in amyotrophic lateral sclerosis. New England Journal of Medicine, 313: 1478, 1985.
26. SLOAN, R. L., BROWN, K. W. and PENTLAND, B.: Fluoxetine as a treatment for emotional lability after brain injury. Brain Injury, 6: 315-319, 1992.
27. SELIGER, G. M., HORNSTEIN, A., FLAX, J. et al.: Fluoxetine improves emotional incontinence. Brain Injury, 6: 267-270, 1992.
28. MUKAND, J., KAPLAN, M., SENNO, R. G. et al.: Pathological crying and laughing: treatment with sertraline. Archives of Physical Medicine and Rehabilitation, 77: 1309-1311, 1996.
29. DEREX, L., OSTROWSKY, K., NIGHOGHOSSIAN, N. et al.: Severe pathological crying after left anterior choroidal artery infarct: reversibility with paroxetine treatment. Stroke, 28: 1464-1466, 1997.
30. BALDWIN, D. and JOHNSON, F. N.: Tolerability and safety of citalopram. Reviews in Contemporary Pharmacotherapy, 6: 45-55, 1995.
31. DUNBAR, G. C.: An interim overview of the safety and tolerability of paroxetine. Psychiatrica Scandinavica, 80 (Suppl. 350): 135-137, 1989.